CADTH | Evidence Driven
CADTH | Evidence Driven

Sonidegib (Odomzo) for Basal Cell Carcinoma - Details

Details

Files
Generic Name:
Sonidegib
Project Status:
Complete
Therapeutic Area:
Basal Cell Carcinoma
Manufacturer:
Sun Pharma Canada Inc.
Brand Name:
Odomzo
Project Line:
Reimbursement Review
Project Number:
PC0215-000
NOC Status at Filing:
Post NOC
Strength:
200 mg
Tumour Type:
Skin and Melanoma
Indications:
Basal Cell Carcinoma (BCC)
Funding Request:
For the treatment of adult patients with histologically confirmed locally advanced basal cell carcinoma (laBCC) that is not amenable to radiation therapy or curative surgery.
Review Status:
Notification to Implement Issued
Sponsor:
Sun Pharma Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation:

Files

Sonidegib (Odomzo) BCC – pERC Final Recommendation Final Recommendation April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – Final Economic Guidance Report Guidance Report April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – Final Clinical Guidance Report Guidance Report April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – pERC Initial Recommendation Initial Recommendation March 4, 2021 View PDF
Sonidegib (Odomzo) BCC – PAG Feedback on Initial Recommendation Feedback April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – Manufacturer Feedback on Initial Recommendation Feedback April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – Patient Advocacy Group Feedback on Initial Recommendation Feedback April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – Clinician Feedback on Initial Recommendation Feedback April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – Patient Advocacy Group COI Declarations COI Declarations April 29, 2021 View PDF
Sonidegib (Odomzo) BCC – Clinician COI Declarations COI Declarations April 29, 2021 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 29, 2021